Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.51 |
| ▸ | F13A1 | P00488 | 2/20 | 0.51 |
| ▸ | TGM2 | P21980 | 2/20 | 0.51 |
| ▸ | TGM1 | P22735 | 2/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | MMP7 | P09237 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3620573 | 0.95 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL504558 | 0.95 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL1103933 | 0.93 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL2492947 | 0.93 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL15084704 | 0.93 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL27494827 | 0.89 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL31628374 | 0.88 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL18592896 | 0.88 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL28659790 | 0.88 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL6351725 | 0.86 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070277-A | Androgen receptor PROTAC | 葛兰素史密斯克莱知识产权发展有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4727591-A1 | SMARCA2 DEGRADERS AND USES THEREOF | Astrazeneca AB (SE) | 2026-04-22 | — | — | EP | disclosed |
| US-12595253-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| EP-4709486-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Celgene Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4709389-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Celgene Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12577231-B2 | Androgen receptor PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| US-20260021095-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260001865-A1 | ANDROGEN RECEPTOR PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-01 | — | — | US | disclosed |
| US-20250367193-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS INC (DE) | 2025-12-04 | — | — | US | disclosed |
| WO-2025235331-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRAZOLOPYRIMIDINE DERIVATIVES FOR DEGRADING CERTAIN CYCLIN-DEPENDENT KINASE VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20110245227-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| EP-2170864-B1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-14 | — | — | EP | disclosed |
| US-8003796-B2 | Pyridone GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2170864-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-22 | — | — | US | disclosed |
| WO-2009012275-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021095-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | PSMB2, PSMB7, MDM2 | SMN1; SMN2 4123/4885NPC1 3876/4885RAB9A 2931/4885 |
| US-12595253-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | JAK1, JAK3, JAK2 | SMN1; SMN2 2425/4885NPC1 1328/4885RAB9A 3094/4885 |
| US-20250367193-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | CDK2, SKP2, CCNK | SMN1; SMN2 2161/4885NPC1 3655/4885RAB9A 2721/4885 |
| US-20260001865-A1 | ANDROGEN RECEPTOR PROTACS | AR, CRBN, PSMA3 | SMN1; SMN2 4159/4885NPC1 2203/4885RAB9A 3329/4885 |
| US-20110245227-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR65, GPR27 | SMN1; SMN2 2669/4885NPC1 2115/4885RAB9A 890/4885 |
| US-12577231-B2 | Androgen receptor PROTACS | AR, CRBN, PSMA3 | SMN1; SMN2 4159/4885NPC1 2203/4885RAB9A 3329/4885 |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | SMN1; SMN2 4419/4885NPC1 488/4885RAB9A 2557/4885 |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR65, GPR27 | SMN1; SMN2 2776/4885NPC1 1988/4885RAB9A 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.